Proteonomix, Inc. OTC: PROT is our new pick. This is a low float stock that trades just over $5. As of the last report on pinksheets.com, PROT has 709,000 shares in the float with only 3,777,874 outstanding. This stock can move fast! PROT works with Stem Cells to fight diseases, owns a Sperm Bank In NY, and is developing ant-aging skin products.
Check out the profile at http://shazamstocks.com/profiles/prot/index.php
Proteonomix, Inc is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives with an initial focus on diabetes and cardiac diseases.
Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include, but are not limited to, cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.
Their mission is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.
National Stem Cell, their operating subsidiary, is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. In addition to its work with stem cell therapeutics, the company is also working to leverage its commercial infrastructure and product development capabilities of its wholly-owned subsidiary The Sperm Bank of NY. The company's investigational products are focused on the improvement of the quality of life for patients and their families.
1) Through their operating subsidiary, National Stem Cell, they have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Their initial focus in stem cell therapeutics is to achieve a leadership position in:the development of identification biomarkers (a biomarker is a substance used as an indicator of a biological state which refers to the complete range of genes found in biological structure and processes of the living body, including the nervous system, the endocrine system, and our senses of sight, hearing, taste, smell, and touch. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention) cell derivatives, and cellular proteins.
the development of stem cell therapies for disease and injury; and
the performance of reproductive cell/tissue laboratory services.
They need to test these technologies and therapies before commercialization.
They have identified stem cells in the human pancreas and have applied for patents for cell surface markers (the molecules present on the surface of each cell which define the cell on what receptors are present - a technique often used to associate cells with certain immune functions) for these pancreatic stem cells as well as methods for their isolation. Based on the fact that these cells are autologous (from same person) rather than from a non-related donor, they anticipate that the cells that they are able to isolate will substantially reduce rejection when transplanted into the liver of the same diabetic patient. The company is performing further research in this area with the University of Miami.
2) Through National Stem Cell, they have developed a patent-pending container device for cryopreservation of stem cells (the process where cells are preserved by cooling to low sub-zero temperatures) that they believe will provide significant improvements in viable cell recovery and contaminant protection, both in freezing and thawing stem cells, than is found with cryostorage containers currently in use.
2) Through National Stem Cell, they have developed a patent-pending container device for cryopreservation of stem cells (the process where cells are preserved by cooling to low sub-zero temperatures) that they believe will provide significant improvements in viable cell recovery and contaminant protection, both in freezing and thawing stem cells, than is found with cryostorage containers currently in use.
3) Multiple cosmetic products have been developed. The products are based on their patents describing their Secreted Matrix TM technology. These products are in production and their launch is scheduled for 2010.
4) Laboratory services are provided by their wholly owned, accredited and operating reproductive cell/tissue banking service (sperm, ova, ovarian tissue, testicular tissue and embryos). It is anticipated that their laboratory services will provide advanced technologies and procedures for the collection, laboratory testing, bio-genetic typing, processing and cryogenic storage of stem cells from both umbilical cord and peripheral blood. Umbilical cord blood stem cells and reproductive cells are processed and banked for both allogeneic (transfer from one person to another) and autologous (derived from and used by the same individual) therapeutic transplantation for a variety of medical disorders, including leukemia and lymphoma with stem cells and infertility with sperm cells. They have developed and implemented a unique, effective and comprehensive strategy for the marketing of their services and products on a national and international scale for applications in stem cell therapeutics together with cell-tissue laboratory services.
Proteonomix, Inc., a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy. The stem cell therapy involves introduction of healthy new stem cells to repair and replace damaged or lost cells. The company's proprietary product is SECRETED MATRIX to serve antaging and damaged skin. It is also developing a platform that would allow for the growth of contaminant-free human embryonic stem cell lines. In addition, it focuses on the development of umbilical cord blood bank for the transplantation of umbilical cord blood stem cells that have been identified as treatment for various diseases.Their mission is to advance the science of regenerative medicine using their innovative approach to stem cell therapeutics. In addition to making therapies available to a wider audience, they aim to further develop the extraordinary potential of their proprietary proteins in treating a broad array of illnesses. Proteonomix’s research and development is focused on stem cell therapies for diabetes and cardiac injury. They have plans to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells that will serve as a catalyst for bringing feasible therapies to market. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include but are not limited to cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.
Umbilical cord blood stem cells are already recognized as a viable treatment for more than 80 diseases, a number that will continue to grow. With this in mind, they are preparing to establish a cord blood bank that employs proprietary technology that will lead to a significant increase the donor-recipient match rate. They will also be launching a genetic diversity program to increase participation of minority groups that are currently under-represented in the pool of available cord blood stem cell units.
No comments:
Post a Comment